United Kingdom In Vivo Contract Research Organization Market Insight
The United Kingdom In Vivo Contract Research Organization Market is growing at an 7.92% CAGR, driven by rising hypothyroidism prevalence, growing thyroid health awareness, and NHS screening programs, the market expands with levothyroxine therapies, combination treatments, improved diagnostics, and pharmaceutical innovations enhancing outcomes and quality
United Kingdom In Vivo Contract Research Organization Market Insights Forecasts to 2035
- The United Kingdom In Vivo Contract Research Organization Market Size Was Estimated at USD 217.6 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 7.92% from 2025 to 2035
- The United Kingdom In Vivo Contract Research Organization Market Size is Expected to Reach USD 466.2 Million by 2035
Notable Insights for United Kingdom In Vivo Contract Research Organization Market
- By service type, efficacy and safety pharmacology studies dominate with approximately 35–45% share, driven by strong early-stage drug development and regulatory safety requirements.
- By study model, rodent-based in vivo studies account for around 60–70% share due to cost efficiency, reproducibility, and strong translational relevance.
- Increasing pharmaceutical outsourcing has led to over 50–60% of preclinical research projects being conducted through CRO partnerships in the UK.
- Biotechnology and pharmaceutical firms represent the primary end users, contributing nearly 70–80% of total in vivo research demand across the market
- Growing focus on biologics and gene therapy is driving a 20–30% higher demand growth rate for specialized in vivo models and advanced toxicity testing platforms compared to traditional studies
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom In Vivo Contract Research Organization Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom In Vivo Contract Research Organization Market
- Charles River Laboratories
- Envigo
- ICON plc
- Laboratory Corporation of America (Covance)
- WuXi AppTec
- Syngene International
- Medpace
- Evotec
- Others
Recent Developments:
- In March 2026: Sygnature Discovery appointed Susanne Back as Head of In Vivo Pharmacology, strengthening UK CRO capabilities with 30+ scientists supporting advanced preclinical drug discovery and translational research services platforms.
- In February 2026: Sygnature Discovery launched a brand relaunch and new website highlighting its “Design, Make, Test, Analyse” (DMTA) model, strengthening UK in vivo CRO integrated drug discovery capabilities.
Market Segmentation:
United Kingdom In Vivo Contract Research Organization Market, By Service Type
- Pharmacology Studies
- Toxicology Studies
- Disease Model Development
- Others
United Kingdom In Vivo Contract Research Organization Market, By Model Type
- Rodent Models
- Non-Rodent Models
- Genetically Modified Models
United Kingdom In Vivo Contract Research Organization Market, By End User
- Pharmaceutical Companies
- Biotechnology Companies
- Academic & Research Institutes
- Others
United Kingdom In Vivo Contract Research Organization Market, By Application
- Oncology
- Neurology
- Cardiovascular Diseases
- Infectious Diseases
- Metabolic Disorders
Expert Views:
The UK In Vivo Contract Research Organization Market is expected to witness steady growth due to increasing outsourcing of preclinical research by pharmaceutical and biotechnology companies. Experts highlight that rising complexity in drug development, particularly in biologics, gene therapy, and precision medicine, is driving demand for advanced in vivo models and specialized CRO services. Strong regulatory frameworks and the UK’s robust life sciences ecosystem further support market expansion. Continued investment in translational research and advanced animal modeling technologies is expected to strengthen long-term growth through 2035.